Orchard Therapeutics PLCOrchard Therapeutics PLC - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This ESG score for Orchard Therapeutics PLC represents the company's transparency towards the UN SDGs. Alternative companies in the scoring peer group for Orchard Therapeutics PLC are displayed. The ESG score covers 17 United Nations Sustainable Development Goals including: 'No Poverty', 'Climate Action' and 'Partnerships for the Goals'.

Orchard Therapeutics PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 1.6, social score of 6.4 and governance score of 6.7.

SDG Transparency Score for Orchard Therapeutics PLC 
Low
0 - 3

5.2

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Orchard Therapeutics PLC 
1.6

Environmental

6.4

Social

6.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
912Vivanza Biosciences Ltd
5.3
High
912ValiRx PLC
5.3
High
958Orchard Therapeutics PLC
5.2
High
958Altimmune Inc
5.2
High
958Agios Pharmaceuticals Inc
5.2
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Orchard Therapeutics PLC have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC report the average age of the workforce?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose cybersecurity risks?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC offer flexible work?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC conduct supply chain audits?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Orchard Therapeutics PLC conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose water use targets?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Orchard Therapeutics PLC have a product recall in the last two years?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose incidents of discrimination?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Orchard Therapeutics PLC issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose parental leave metrics?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Orchard Therapeutics PLC involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose its waste policy?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC report according to TCFD requirements?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose energy use targets?

LockedSign up for free to unlock

Does Orchard Therapeutics PLC disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Orchard Therapeutics PLC have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Orchard Therapeutics PLC
These potential risks are based on the size, segment and geographies of the company.

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Sorry!

Failed to process!